The most commonly recommended first-line treatment for<unk>  is psoralen plus ultraviolet A (PUVA therapy). PUVA is a photochemotherapy that involves topical or oral administration of the photosensitizing drug psoralen followed by skin exposure to ultraviolet radiation. Systemic treatments of<unk>  often lead to resistance; as such, additional treatment options are often necessary in advanced disease. Other treatments that have been suggested, however, larger and more extensive research is needed to identify effective treatment strategies for this disease. Suggested treatments include light therapy, ultraviolet light (mainly NB-UVB 312 nm), topical steroids, topical and systemic chemotherapies, local superficial radiotherapy, the histone deacetylase inhibitor vorinostat, total skin electron radiation, photopheresis, systemic therapies (e.g. retinoids, rexinoids), and biological therapies (e.g. interferons). Treatments are often used in combination. Due to the possible adverse effects of treatment options in early disease it is recommended to begin therapy with topical and skin-directed treatments before progressing to more systemic therapies. In 2010, the U.S. Food and Drug Administration granted orphan drug designation for naloxone lotion, a topical opioid receptor competitive antagonist used as a treatment for pruritus in cutaneous T-cell lymphoma. Mogamulizumab is a CCR4 monoclonal antibody which has been shown to improve progression-free survival. It was approved by the US FDA in 2018 for use in people with relapsed or refractory<unk>  or Sézary disease. There is no evidence to support the use of acitretin or extracorporeal photopheresis (ECP: a type of phototherapy) for treating people with<unk> . There is also no evidence to support the combination treatment of PUVA and intralesional IFN-α or PUVA and bexarotene. Children Treatment for adults and children with<unk>  often differs because of the safety profiles of modalities. Narrowband UV-B is commonly considered for children, as opposed to Psoralen with UV-A, mechlorethamine hydrochloride, or oral bexarotene, which is often used in adults.
Mycosis fungoides
Sycosis vulgaris
Keratoderma climactericum
Tinea versicolor
Lymphomatoid papulosis
Actinic granuloma
Diabetic dermadrome
Granuloma faciale